Piperazine

Antepar, Bryrel, Multifuge (piperazine) is a small molecule pharmaceutical. Piperazine was first approved as Antepar on 1982-01-01. It is used to treat ascariasis, enterobiasis, and nematode infections in the USA. It is known to target 5-hydroxytryptamine receptor 2B, muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M3, 5-hydroxytryptamine receptor 1D, muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 1E, muscarinic acetylcholine receptor M5, 5-hydroxytryptamine receptor 7, muscarinic acetylcholine receptor M1, and 5-hydroxytryptamine receptor 6.